Covid19-ITS am 30.9.24: R=1,12 ITS-Belegung: 308[+3 Kinder] (+13%/+14%) - 7T-Mittel: 282 (+2%/+21%) ITS-Erstaufnahmen: 40 (Vorwoche 56) - 7T-Mittel: 37,3 (-6%/+6%) R-Werte: - aus C19-Belegung (7TM): 1,12 (-0,01/+0,07) - aus C19-Erstaufnahmen (14TQ): 1,14 (Âą0/+0,03)
Hierhin gehĂśrt es: Covid19-ITS am 29.9.24: R=1,13 ITS-Belegung: 273[+3 Kinder] (Âą0%/+7%) - 7T-Mittel: 276 (+1%/+23%) ITS-Erstaufnahmen: 21 (Vorwoche 21) - 7T-Mittel: 37,3 (Âą0%/+36%) R-Werte: - aus C19-Belegung (7TM): 1,13 (-0,01/+0,10) - aus C19-Erstaufnahmen (14TQ): 1,14 (Âą0/+0,08)
Covid19-ITS am 29.9.24: R=1,13 ITS-Belegung: 273[+3 Kinder] (Âą0%/+7%) - 7T-Mittel: 276 (+1%/+23%) ITS-Erstaufnahmen: 21 (Vorwoche 21) - 7T-Mittel: 37,3 (Âą0%/+36%) R-Werte: - aus C19-Belegung (7TM): 1,13 (-0,01/+0,10) - aus C19-Erstaufnahmen (14TQ): 1,14 (Âą0/+0,08)
Relatively unimpressive pace of SARS2 developing resistance to nirmatrelvir, in comparison to (say) HIV to HIV drugs, was predictable, since it's rarely a significant part of its selective environment. They are showing now in immunocompromised. jamanetwork.com/journals/jam...
Nirmatrelvir is the antiviral component of nirmatrelvir/ritonavir, the first US Food and Drug Administrationâapproved oral antiviral for treatment of COVID-19 in adults. The widespread use of nirmatre...
Covid19-ITS am 28.9.24: R=1,14 ITS-Belegung: 273[+2 Kinder] (+0%/+13%) - 7T-Mittel: 274 (+2%/+25%) ITS-Erstaufnahmen: 25 (Vorwoche 28) - 7T-Mittel: 37,7 (-1%/+39%) R-Werte: - aus C19-Belegung (7TM): 1,14 (Âą0/+0,13) - aus C19-Erstaufnahmen (14TQ): 1,14 (Âą0/+0,08)
Sero-testing for antibodies should offer a definitive of if it were indeed Bird Flu? Irrespective: this is worrisome to have continue going on like this. And as SARS2 showed, USA is woefully & by choice unprepared for next nasty zoonotic spill over.
Covid19-ITS am 27.9.24: Râď¸1,14 ITS-Belegung: 272[0 Kinder] (-5%/+20%) - 7T-Mittel: 269 (+5%/+26%) ITS-Erstaufnahmen: 23 (Vorwoche 35) - 7T-Mittel: 37,7 (-4%/+47%âźď¸) R-Werte: - aus C19-Belegung (7TM): âď¸1,14 (+0,01/+0,13) - aus C19-Erstaufnahmen (14TQ): âď¸1,14 (-0,02/+0,08)
I donât think itâs an exaggeration to say that weâre living through an unprecedented experiment in mass exposure to a deadly virus with unknown long-term effects on health and the immune system. And still no mitigations in place. #COVIDisNotOver#SARS2www.theguardian.com/world/2024/s...
Immunologists push for increase in testing and more widespread vaccine booster rollout as new variant, XEC, emerges
Covid19-ITS am 26.9.24: Râď¸1,13âźď¸ ITS-Belegung: 285[+1 Kind] (+1%/+39%âźď¸) - 7T-Mittel: 263 (+5%/+24%) ITS-Erstaufnahmen: 51 (Vorwoche 31) - 7T-Mittel: 39,3 (+8%/+63%âźď¸) R-Werte: - aus C19-Belegung (7TM): âď¸1,13 (+0,03/+0,12) - aus C19-Erstaufnahmen (14TQ): âď¸1,16âźď¸ (+0,02/+0,14)
Covid19-ITS am 25.9.24: Râď¸1,10âźď¸ ITS-Belegung: 283[+1 Kind] (+1%/+37%âźď¸) - 7T-Mittel: 252 (+5%/+18%) ITS-Erstaufnahmen: 43 (Vorwoche 31) - 7T-Mittel: 36,6 (+6%/+51%âźď¸) R-Werte: - aus C19-Belegung (7TM): âď¸1,10 (+0,03/+0,08) - aus C19-Erstaufnahmen (14TQ): âď¸1,14âźď¸ (+0,02/+0,11)